Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1971 1
1973 1
1975 4
1977 1
1978 2
1979 1
1981 2
1982 2
1984 2
1985 1
1986 4
1987 1
1988 3
1989 1
1990 1
1991 2
1992 1
1997 2
1998 1
1999 1
2000 1
2001 1
2006 2
2007 2
2008 1
2009 4
2010 3
2011 7
2012 10
2013 6
2014 6
2015 7
2016 5
2017 3
2018 4
2019 1
2020 1
2021 2
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

93 results
Results by year
Filters applied: . Clear all
Page 1
Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens.
Read AF, Baigent SJ, Powers C, Kgosana LB, Blackwell L, Smith LP, Kennedy DA, Walkden-Brown SW, Nair VK. Read AF, et al. Among authors: kennedy da. PLoS Biol. 2015 Jul 27;13(7):e1002198. doi: 10.1371/journal.pbio.1002198. eCollection 2015 Jul. PLoS Biol. 2015. PMID: 26214839 Free PMC article.
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Younes A, et al. Among authors: kennedy da. N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965. N Engl J Med. 2010. PMID: 21047225 Free article. Clinical Trial.
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S, Forero-Torres A, Moskowitz CH, Connors JM, Engert A, Larsen EK, Kennedy DA, Sievers EL, Chen R. Younes A, et al. Among authors: kennedy da. J Clin Oncol. 2012 Jun 20;30(18):2183-9. doi: 10.1200/JCO.2011.38.0410. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454421 Free PMC article. Clinical Trial.
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Fenton K, Huebner D, Pinelli JM, Kennedy DA, Shustov A. Pro B, et al. Among authors: kennedy da. Blood. 2017 Dec 21;130(25):2709-2717. doi: 10.1182/blood-2017-05-780049. Epub 2017 Oct 3. Blood. 2017. PMID: 28974506 Free PMC article. Clinical Trial.
The economics of managing evolution.
Day T, Kennedy DA, Read AF, McAdams D. Day T, et al. Among authors: kennedy da. PLoS Biol. 2021 Nov 16;19(11):e3001409. doi: 10.1371/journal.pbio.3001409. eCollection 2021 Nov. PLoS Biol. 2021. PMID: 34784349 Free PMC article.
Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA, Levine P, Yang J, Bartlett NL. Jacobsen ED, et al. Among authors: kennedy da. Blood. 2015 Feb 26;125(9):1394-402. doi: 10.1182/blood-2014-09-598763. Epub 2015 Jan 8. Blood. 2015. PMID: 25573987 Free article. Clinical Trial.
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Pro B, et al. Among authors: kennedy da. J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614995 Clinical Trial.
Laboratory safety.
Collins CH, Kennedy DA. Collins CH, et al. Among authors: kennedy da. Science. 1998 Nov 20;282(5393):1419-20. doi: 10.1126/science.282.5393.1419c. Science. 1998. PMID: 9867646 No abstract available.
93 results